Business Context and Reporting Period
Company: Allogene Therapeutics, Inc. (ALLO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Allogene is a clinical-stage immuno-oncology company developing "off-the-shelf" allogeneic CAR T cell therapies for cancer and autoimmune diseases. The company focuses on three core programs: cema-cel (ALLO-501A) for Large B-Cell Lymphoma (LBCL), ALLO-316 for Renal Cell Carcinoma (RCC), and ALLO-329 for Autoimmune Diseases (AID). The company operates its own manufacturing facility, Cell Forge 1, in Newark, California.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0.02 million | $0.095 million |
| Net Loss | $(257.6) million | $(327.3) million |
| Operating Expenses | $273.2 million | $327.8 million |
| Research & Development (R&D) | $192.3 million | $242.9 million |
| General & Administrative (G&A) | $65.2 million | $71.7 million |
| Cash, Cash Equivalents & Investments | $373.1 million | $448.7 million |
| Accumulated Deficit | $(1.82) billion | $(1.56) billion |
| Net Cash Used in Operating Activities | $(200.3) million | $(237.7) million |
Note: Revenue is derived primarily from collaboration agreements with Overland Therapeutics. The company has no product sales revenue.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately 21% (from $327.3 million to $257.6 million), driven primarily by a $50.6 million reduction in R&D expenses and a $6.5 million reduction in G&A expenses.
- Cost Reduction Initiatives: In January 2024, the company implemented a 22% reduction in workforce, resulting in lower personnel costs and stock-based compensation.
- Impairment Charges: The company recorded a $15.7 million impairment charge for long-lived assets (primarily right-of-use assets and leasehold improvements) due to subleasing decisions and market conditions, compared to $13.2 million in 2023.
- Capital Raise: In May 2024, the company completed a registered offering, raising net proceeds of $105.2 million. Additionally, $6.8 million was raised through At-The-Market (ATM) offerings.
- Investment Income: Interest and other income increased to $20.2 million from $18.3 million due to higher yields on cash and investments.
Guidance, Outlook, and Risks
Outlook and Milestones
- Cash Runway: Management expects current cash resources ($373.1 million) to fund operations into the second half of 2026.
- ALPHA3 Trial (cema-cel): A pivotal Phase 2 trial for 1L consolidation in LBCL is ongoing with 40 sites activated. An interim analysis to select the lymphodepletion regimen is anticipated in mid-2025. Primary efficacy readout is expected around year-end 2026, with a Biologics License Application (BLA) targeted for 2027.
- ALLO-316 (RCC): Enrollment in the Phase 1b expansion cohort is complete. Additional data is expected in mid-2025. The product received Regenerative Medicine Advanced Therapy (RMAT) designation in October 2024.
- ALLO-329 (Autoimmune): The FDA cleared the IND for the RESOLUTION Phase 1 trial in January 2025. Trial initiation is targeted for mid-2025, with proof-of-concept data anticipated by year-end 2025.
Key Risks and Contingencies
- Capital Needs: The company anticipates substantial net losses in the future and will require additional financing to complete development and commercialization. Failure to secure funding could force delays or discontinuation of programs.
- Regulatory and Clinical Uncertainty: No CAR T therapy has been approved for first-line consolidation in LBCL. The ALPHA3 trial relies on a companion diagnostic (Foresight Diagnostics' CLARITY assay) which faces regulatory and logistical risks.
- Intellectual Property Disputes: Cellectis has initiated arbitration against Servier regarding the Servier-Cellectis Agreement, which underpins Allogene's access to TALEN gene-editing technology for its oncology products. A negative outcome could jeopardize the cema-cel program.
- Manufacturing Reliance: While Allogene operates Cell Forge 1, it relies on third parties for certain raw materials and the manufacturing of ALLO-647. A recent acquisition of a Catalent site by Novo Nordisk requires Allogene to transfer ALLO-647 manufacturing, introducing potential delays.
- Internal Controls: A material weakness in internal controls over financial reporting identified in prior years was remediated as of December 31, 2024.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $373.1 million cash balance against the projected burn rate to confirm the "second half of 2026" runway estimate.
- ALPHA3 Enrollment: Monitor patient enrollment rates and the MRD-positive conversion rate, as high screen failure rates could delay the trial.
- Servier/Cellectis Arbitration: Track the status of the arbitration between Cellectis and Servier, as a termination of the underlying agreement could threaten Allogene's core technology license.
- ALLO-647 Manufacturing Transfer: Confirm the timeline and regulatory approval for transferring ALLO-647 manufacturing to a new site following the Novo Nordisk/Catalent acquisition.
- Companion Diagnostic Approval: Assess the regulatory progress of Foresight Diagnostics' CLARITY assay, which is critical for the commercialization of cema-cel.